NLRP3 inflammasome and the downstream pro-inflammatory cytokines IL-1β and IL-18 are attractive pharmaceutical candidates for therapeutic intervention of atherosclerosis, and selectively neutralizing these cytokines has been shown to be available in the context. Here, IL1B is linked to atherosclerosis.